Clinical Trial Update: Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update examining how infusion timing affects pathologic response to neoadjuvant immunotherapy in resectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING